Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

Research Developments in Atopic Dermatitis
08/09/2020 7 min Temporada 1 Episodio 6

Listen "Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis"

Descargar episodio Ver en sitio original

Episode Synopsis

This poster was presented by Dr. Silverberg and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This overview is provided by Dr. Alan Fleischer.

More episodes of the podcast Research Developments in Atopic Dermatitis

Introduction and Overview 08/09/2020
Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis 08/09/2020
Safety, Efficacy and Pharmacokinetics of Crisaborole Ointment 2% in Infants Age Three to Less Than 24 Months with Mild-to-Moderate Atopic Dermatitis 08/09/2020
Association Between an Itch-Free State in Atopic Dermatitis Treated with Ruxolitinib Cream and Systemic Inflammatory Mediators 08/09/2020
Dupilumab Treatment for up to Three Years Demonstrates Sustained Efficacy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Liberty AD Adult Open Label Extension 08/09/2020
Peak Pruritus Numeric Rating Scale, the PPNRS, Response with Abrocitinib in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial 08/09/2020
Dupilumab Treatment Results in Rapid Improvement in Itch in Adults and Adolescent Patients with Moderate to Severe Atopic Dermatitis 08/09/2020
Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: An Analysis of a Retrospective Claims Database 08/09/2020
Other posters of interest 08/09/2020
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA